Feedback / Questions
agerafenib (RXDX-105) - Roche, Daiichi Sankyo
Ignyta: ENA 2016
(Ignyta)
-
Dec 4, 2016 -
"5 out of 9 RET inhibitor-naïve patients with RET fusion-positive tumors have a RECIST response, 4 confirmed (1 CR, 3 PR) and 1 unconfirmed response (uPR), for a preliminary ORR of 56%"
P1 data
•
Oncology
https://ignyta.com/wp-content/uploads/2016/11/Ignyta-RXDX-105-2016-ENA-Poster-Final_21Nov2016.pdf
Dec 4, 2016
SHARE THIS
Print
Email
More sharing
Reddit
StumbleUpon
Delicious